EA201992135A1 - Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета - Google Patents

Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета

Info

Publication number
EA201992135A1
EA201992135A1 EA201992135A EA201992135A EA201992135A1 EA 201992135 A1 EA201992135 A1 EA 201992135A1 EA 201992135 A EA201992135 A EA 201992135A EA 201992135 A EA201992135 A EA 201992135A EA 201992135 A1 EA201992135 A1 EA 201992135A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
pancreatic
source
stem cells
surrogate
Prior art date
Application number
EA201992135A
Other languages
English (en)
Russian (ru)
Inventor
Уилльям Л. Раст
Original Assignee
Серексис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Серексис, Инк. filed Critical Серексис, Инк.
Publication of EA201992135A1 publication Critical patent/EA201992135A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1329—Cardiomyocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/22—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
EA201992135A 2012-06-26 2013-06-24 Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета EA201992135A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261664259P 2012-06-26 2012-06-26

Publications (1)

Publication Number Publication Date
EA201992135A1 true EA201992135A1 (ru) 2020-02-05

Family

ID=48746139

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201992135A EA201992135A1 (ru) 2012-06-26 2013-06-24 Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета
EA201590088A EA033954B1 (ru) 2012-06-26 2013-06-24 Неплюрипотентные клетки-предшественники суррогатных клеток поджелудочной железы и способ их получения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201590088A EA033954B1 (ru) 2012-06-26 2013-06-24 Неплюрипотентные клетки-предшественники суррогатных клеток поджелудочной железы и способ их получения

Country Status (16)

Country Link
US (2) US9968639B2 (https=)
EP (2) EP2864473B1 (https=)
JP (2) JP6386453B2 (https=)
KR (2) KR102174581B1 (https=)
CN (2) CN113265370A (https=)
AU (2) AU2013280698B2 (https=)
BR (1) BR112014031676A2 (https=)
CA (1) CA2876677C (https=)
DK (1) DK2864473T3 (https=)
EA (2) EA201992135A1 (https=)
ES (1) ES2745704T3 (https=)
IL (2) IL236346B (https=)
IN (1) IN2015DN00281A (https=)
PT (1) PT2864473T (https=)
SG (1) SG11201408717XA (https=)
WO (1) WO2014004341A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106467918B (zh) * 2015-08-18 2020-07-31 中国科学技术大学先进技术研究院 一种基于人皮肤细胞的胰岛素分泌细胞的诱导方法及应用
CN105434471A (zh) * 2015-11-26 2016-03-30 深圳爱生再生医学科技有限公司 治疗糖尿病的干细胞制剂及其制备方法
EP3749752A1 (en) * 2018-02-09 2020-12-16 Seraxis, Inc. Pancreatic cells for treating diabetes and methods of generating the same
KR20210077698A (ko) * 2018-10-15 2021-06-25 사이니티 가부시키가이샤 저분자 화합물에 의한 내배엽 조직 또는 기관 유래 세포로부터의 줄기/전구 세포의 제작 방법
WO2021117840A1 (ja) * 2019-12-11 2021-06-17 国立大学法人 東京大学 Ｍｙｃｌの一過性発現による増殖可能な膵島前駆細胞様細胞の誘導とインスリン陽性細胞への分化誘導
WO2023278382A1 (en) 2021-06-29 2023-01-05 Staffan Holmin Endoluminal delivery cannula
US20230330264A1 (en) 2022-04-15 2023-10-19 Smartcella Solutions Ab COMPOSITIONS AND METHODS FOR EXOSOME-MEDIATED DELIVERY OF mRNA AGENTS
JP2026505821A (ja) 2023-02-03 2026-02-18 セラクシス，インコーポレーテッド 治療細胞およびそれらに関連する方法
WO2025029826A1 (en) 2023-07-31 2025-02-06 Seraxis, Inc. Modified therapeutics cells and methods relating to the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861313A (en) * 1995-06-07 1999-01-19 Ontogeny, Inc. Method of isolating bile duct progenitor cells
AU2376200A (en) 1999-01-07 2000-07-24 Incyte Pharmaceuticals, Inc. Insulin-synthesis genes
US6815203B1 (en) * 1999-06-23 2004-11-09 Joslin Diabetes Center, Inc. Methods of making pancreatic islet cells
US20010046489A1 (en) 1999-12-06 2001-11-29 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US20030082155A1 (en) 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
AU2003268534A1 (en) 2002-09-06 2004-03-29 Amcyte Inc. Cd56 positive human adult pancreatic endocrine progenitor cells
CA2527626A1 (en) 2003-06-20 2004-12-29 Vrije Universiteit Brussel Method of generating islet beta-cells from exocrine pancreatic cells
CA2581424A1 (en) * 2004-03-09 2005-09-22 Gang Xu Methods for generating insulin-producing cells
US20060029987A1 (en) 2004-08-06 2006-02-09 Applera Corporation Diagnosis of pancreatic cancer by using pancreatic targets
US7807459B2 (en) 2005-09-27 2010-10-05 Reneuron, Inc. EphA4-positive human adult pancreatic endocrine progenitor cells
US20100137202A1 (en) * 2006-07-19 2010-06-03 University Of Florida Research Foundation Compositions for reprogramming a cell and uses therefor
WO2008112278A2 (en) 2007-03-12 2008-09-18 The Trustees Of Columbia University In The City Of New York Methods and compositions for modulating insulin secretion and glucose metabolism
CA2692634C (en) 2007-11-09 2014-05-27 Rnl Bio Co., Ltd Method for isolating and culturing adult stem cells derived from human amniotic epithelium
WO2009128533A1 (ja) 2008-04-18 2009-10-22 国立大学法人名古屋大学 間葉系幹細胞およびその生産方法
CN102083964B (zh) * 2008-05-09 2013-06-12 格拉斯哥大学大学行政评议会 与基于细胞的疗法相关的材料和方法
WO2010022395A2 (en) * 2008-08-22 2010-02-25 President And Fellows Of Harvard College Methods of reprogramming cells
JP2012513218A (ja) * 2008-12-23 2012-06-14 ヴィヴォスクリプト，インコーポレイテッド 遺伝子改変を伴わずに細胞を再プログラミングするための組成物および方法
WO2011032025A2 (en) * 2009-09-10 2011-03-17 The Salk Institute For Biological Studies Adipose-derived induced pluripotent stem cells
RU2663339C1 (ru) 2010-05-12 2018-08-03 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
SG187830A1 (en) * 2010-08-22 2013-03-28 Univ Ramot Induced pluripotent stem cells derived from human pancreatic beta cells
EP2611907B1 (en) * 2010-08-31 2016-05-04 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
CN103210082A (zh) * 2010-09-15 2013-07-17 雷蒙特亚特特拉维夫大学有限公司 扩增胰岛β细胞和使其再分化的方法
WO2012044486A1 (en) * 2010-09-28 2012-04-05 Baylor Research Institute Induction of pancreatic stem cells by transient overexpression of reprogramming factors and pdxi selection

Also Published As

Publication number Publication date
US20150231181A1 (en) 2015-08-20
JP6856586B2 (ja) 2021-04-07
KR20190141263A (ko) 2019-12-23
DK2864473T3 (da) 2019-09-23
CN104640979B (zh) 2021-05-04
KR102058259B1 (ko) 2019-12-23
ES2745704T3 (es) 2020-03-03
AU2013280698A1 (en) 2015-01-22
WO2014004341A1 (en) 2014-01-03
EP3611255A1 (en) 2020-02-19
JP6386453B2 (ja) 2018-09-05
IL236346A0 (en) 2015-02-26
JP2015522281A (ja) 2015-08-06
CA2876677C (en) 2021-09-07
IL266965B (en) 2021-08-31
PT2864473T (pt) 2019-09-27
KR102174581B1 (ko) 2020-11-06
EP2864473B1 (en) 2019-08-21
EP2864473A1 (en) 2015-04-29
KR20150036059A (ko) 2015-04-07
BR112014031676A2 (pt) 2017-10-31
JP2018193394A (ja) 2018-12-06
CN104640979A (zh) 2015-05-20
US20130344594A1 (en) 2013-12-26
AU2019202085A1 (en) 2019-04-18
EA033954B1 (ru) 2019-12-13
EA201590088A1 (ru) 2015-04-30
AU2013280698B2 (en) 2019-01-17
US9968639B2 (en) 2018-05-15
CN113265370A (zh) 2021-08-17
CA2876677A1 (en) 2014-01-03
US9474772B2 (en) 2016-10-25
IL236346B (en) 2019-06-30
SG11201408717XA (en) 2015-02-27
IN2015DN00281A (https=) 2015-06-12
IL266965A (en) 2019-07-31

Similar Documents

Publication Publication Date Title
EA201992135A1 (ru) Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
ZA201509025B (en) Rna-guided transcriptional regulation
JP2012140442A5 (https=)
EA201590488A1 (ru) Способы модификации клеток-хозяев
EA201500172A1 (ru) Модифицированные полипептиды фактора х и их применение
EA201400993A1 (ru) Антитела против рецептора эпидермального фактора роста, активные в определенных условиях, и способы их применения
BR112014031424A2 (pt) tratamento de células pluripotentes
EP2760879C0 (en) PROTEIN ADHESIVES, THEIR PRODUCTION AND USE
DK2838548T5 (en) Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
EA201391773A1 (ru) Клетки-предшественники мезодермальной линии
TN2014000438A1 (en) Anti-fcrn antibodies
MX386776B (es) Composiciones de células t deficientes del receptor de células t.
GB201020995D0 (en) Biological materials and uses thereof
WO2011130624A3 (en) Sustained polypeptide expression from synthetic, modified rnas and uses thereof
WO2014153115A3 (en) Compositions and methods for reprogramming hematopoietic stem cell lineages
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
WO2011163531A3 (en) Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases
TN2014000327A1 (en) Oligonucleotides for modulating gene expression and uses thereof
EP2811023A4 (en) VECTOR SIMULTANEOUSLY EXPRESSING DODECAMER TRAIL AND SUICIDE HSV-TK GENES, AND ANTICANCER THERAPEUTIC AGENT BASED ON STEM CELLS USING THE SAME
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
MX2015008436A (es) Composiciones para permeabilizar celulas sanguineos fijos y sus usos.
EP2999780A4 (en) PLURIPOTENTIAL HUMAN ADULTS FAT TISSUE TREATMENT CELLS: INSULATION, CHARACTERIZATION, AND CLINICAL EFFECTS
MX2013004062A (es) Analogos de ciclosporina.
AU346001S (en) Animal waste and organic matter digester